Cargando…
Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report
INTRODUCTION: Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), is approved as a therapy for unresectable or metastatic melanoma. Immunotherapy-associated pneumonitis is an uncommon event. PATIENT CONCERNS: A 73-year-old man was admitted to our hospital with a history of...
Autores principales: | Ma, Qin, Yang, Lei, Gu, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793440/ https://www.ncbi.nlm.nih.gov/pubmed/33429766 http://dx.doi.org/10.1097/MD.0000000000024018 |
Ejemplares similares
-
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2019) -
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report
por: Jiang, Jian, et al.
Publicado: (2020) -
Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature
por: Song, Jin-cheng, et al.
Publicado: (2017) -
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report
por: Abdou, Yara, et al.
Publicado: (2019) -
Metastatic malignant melanoma from anorectum presenting as an isolated breast tumor: A case report and literature review
por: Yi, Xiaokang, et al.
Publicado: (2022)